Market Research Report
Circulating Tumor Cells (CTC) Market - Growth, Trends, and Forecast (2019 - 2024)
|Published by||Mordor Intelligence LLP||Product code||649744|
|Published||Content info||112 Pages
Delivery time: 2-3 business days
|Circulating Tumor Cells (CTC) Market - Growth, Trends, and Forecast (2019 - 2024)|
|Published: May 1, 2019||Content info: 112 Pages||
The major factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology, rising demand for preventive medicine and companion diagnostics, and growing prevalence of cancer.
The global cancer burden is increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. Lung and breast cancers were the most common and contributed about 12.3% of the total number of new cases that were diagnosed in 2018. Almost half of the cancer prevalence occurs in Asia, and in Europe, one-quarter of the population is suffering from cancer. In the Americas, 21% of the population is suffering from cancer. The increasing cancer burden is due to a number of factors, including population growth and aging and the changing prevalence of certain causes of cancer linked to social and economic development. According to the WHO, in 2018, approximately 70% of the deaths in low and middle-income countries were due to cancer. With this growing burden, prevention of cancer is one of the most significant challenges. Furthermore, according to the Globocan Database, in 2018, it was estimated that the number of new cases would grow from 18.1 million to 29.4 million, between 2018 and 2040. Thus, the increasing prevalence of cancer is one of the major factors that are augmenting the growth of the market.
As per the scope of this report, circulating tumor cells (CTC) refer to the tumor cells that circulate inside the body through the blood circulatory system and lymphatic system. Factors, such as the high prevalence of cancer, advancements in biomedical imaging and bioengineering technology, and increased demand for preventive medicine, with the need for companion diagnostics, drive the circulating tumor cell market globally. The market is segmented by technology, application, and geography.
Negative Enrichment is the Segment by CTC Enrichment Methods is Expected to Dominate the Market
In case of the positive enrichment methods it cannot isolate CTCs depending on heterogeneous properties, but negative enrichment methods can isolate heterogeneous and intact CTCs by specifically eliminating blood cells. The rising prevalence of the various types of cancer is expected to drive the overall growth of the market. The analysis of circulating tumor cells is an increasing interest for monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs, and for research into the mechanisms of disease progression. In addition, negative enrichment has advantages over positive enrichment in isolating CTCs owing to which the market is expected to witness high growth over the forecast period.
North America is Expected to Dominate the Market
In 2018, as per the American Cancer Society, above 15.5% of Americans had a history of cancer by 2016, of which a majority have been diagnosed in the past two years. The highest number of new cases are being reported, such as respiratory system, breast, genital system, and urinary system, with about 1.7 million new cases being reported in 2018. Based on healthcare expenditure, the United States is among the major countries across the world, which spends about 17.1% of its total GDP on healthcare. The expenditure for cancer patients is mostly in breast, lung, and colon and rectum cancers. The United States has one of the highly successful products approved by the US Food and Drug Administration (FDA), CellSearch Circulating Tumor Cell Kit. The product has reimbursement facility through various public and private payers in several states of the country, such as Cigna Government Services, Noridian, and United HealthCare, amongst others. Several universities across the United States, have relied on CTCs applications to advance the practice of pathology and laboratory medicine. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.
The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are Advanced Cell Diagnostics, Inc, Aviva Biosciences, Biocept Inc, Creatv Micro Tech, Inc., LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec, Precision For Medicine formerly ApoCell, and Qiagen NV